Home
VSTM
VSTM News

Latest Verastem Inc. (VSTM) News on November 11, 2025

Verastem Oncology to Present at Upcoming Investor Conferences

Business Wire

6 days ago

Verastem Oncology to Present at Upcoming Investor Conferences

Verastem (VSTM): Rapid 55.7% Revenue Growth Forecast Challenges Persistent Unprofitability Narrative

Simply Wall St.

6 days ago

Verastem (VSTM): Rapid 55.7% Revenue Growth Forecast Challenges Persistent Unprofitability Narrative

Verastem Inc (VSTM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Rising ...

GuruFocus.com

6 days ago

Verastem Inc (VSTM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Rising ...

Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates

Zacks

7 days ago

Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates

Associated Press Finance

7 days ago

Verastem: Q3 Earnings Snapshot

Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Business Wire

7 days ago

Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Verastem (VSTM) Upgraded to Buy: Here's Why

Zacks

7 days ago

Verastem (VSTM) Upgraded to Buy: Here's Why

Verastem, Inc. (VSTM) Delivers Positive Preliminary Data for VS-7375 in Mutant Solid Tumors Treatment

Insider Monkey

12 days ago

Verastem, Inc. (VSTM) Delivers Positive Preliminary Data for VS-7375 in Mutant Solid Tumors Treatment

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors

Business Wire

18 days ago

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors

Verastem (VSTM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Zacks

19 days ago

Verastem (VSTM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025

Business Wire

19 days ago

Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025

Verastem Oncology (VSTM): Assessing Valuation Following Promising KRAS G12D Pancreatic Cancer Trial Update

Simply Wall St.

20 days ago

Verastem Oncology (VSTM): Assessing Valuation Following Promising KRAS G12D Pancreatic Cancer Trial Update

Best Momentum Stocks to Buy for Oct. 21

Zacks

21 days ago

Best Momentum Stocks to Buy for Oct. 21

New Strong Buy Stocks for Oct. 21: NEM, AS and More

Zacks

21 days ago

New Strong Buy Stocks for Oct. 21: NEM, AS and More

MT Newswires

21 days ago

Verastem Says Median Overall Survival Not Reached in Partner's Phase 1/2 Pancreatic Cancer Study; Shares Fall

Are You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great Choice

Zacks

21 days ago

Are You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great Choice

Wall Street Analysts Think Verastem (VSTM) Could Surge 68.11%: Read This Before Placing a Bet

Zacks

22 days ago

Wall Street Analysts Think Verastem (VSTM) Could Surge 68.11%: Read This Before Placing a Bet

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

Business Wire

23 days ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

Verastem’s avutometinib combination shows 31% ORR in ovarian cancer trial

Clinical Trials Arena

4 months ago

Verastem’s avutometinib combination shows 31% ORR in ovarian cancer trial

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

Business Wire

4 months ago

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

MT Newswires

5 months ago

RBC Cuts Price Target on Verastem to $12 From $16, Keeps Outperform, Speculative Risk

MT Newswires

5 months ago

Verastem Doses First Patient in US Study of Oral Cancer Drug VS-7375

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Business Wire

5 months ago

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?

Zacks

5 months ago

Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

Business Wire

5 months ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval

Zacks

5 months ago

VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

Business Wire

5 months ago

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

US High Growth Tech Stocks to Watch in May 2025

Simply Wall St.

5 months ago

US High Growth Tech Stocks to Watch in May 2025

Verastem announces positive Phase 1/2 safety and efficacy results in PDAC

TipRanks

6 months ago

Verastem announces positive Phase 1/2 safety and efficacy results in PDAC

MT Newswires

6 months ago

Verastem Says Pancreatic Cancer Patients in Phase 1/2 Trial of Avmapki Achieve 83% Overall Response Rate

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

Business Wire

6 months ago

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

Tempus partners with Verastem for companion diagnostic development

Medical Device Network

6 months ago

Tempus partners with Verastem for companion diagnostic development

MT Newswires

6 months ago

Tempus AI, Verastem to Develop Diagnostic Test for Ovarian Cancer Combination Treatment

Associated Press Finance

6 months ago

Verastem: Q1 Earnings Snapshot

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

Business Wire

6 months ago

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

FDA grants accelerated approval to avutometinib, defactinib combination

TipRanks

6 months ago

FDA grants accelerated approval to avutometinib, defactinib combination

MT Newswires

6 months ago

B. Riley Adjusts Verastem Price Target to $13 From $12, Maintains Buy Rating

MT Newswires

6 months ago

Mizuho Adjusts Price Target on Verastem to $16 From $8, Maintains Outperform Rating

MT Newswires

6 months ago

RBC Raises Price Target on Verastem to $16 From $14, Keeps Outperform, Speculative Risk

FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer

Benzinga

6 months ago

FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

Business Wire

6 months ago

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

MT Newswires

6 months ago

Verastem Receives US FDA Approval for Drug Combination to Treat Recurrent Ovarian Cancer

Verastem Oncology to Present at Upcoming Investor Conferences

Business Wire

6 months ago

Verastem Oncology to Present at Upcoming Investor Conferences

MT Newswires

6 months ago

B. Riley Adjusts Verastem Price Target to $12 From $9, Maintains Buy Rating

MT Newswires

7 months ago

Verastem Shares Rise After Agreement to Sell Securities Worth Roughly $75 Million

Verastem Oncology Announces $75 million Private Placement

Business Wire

7 months ago

Verastem Oncology Announces $75 million Private Placement

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

Business Wire

7 months ago

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

Verastem Oncology to Report Q1 Earnings: What's in the Cards?

Zacks

7 months ago

Verastem Oncology to Report Q1 Earnings: What's in the Cards?

Top Cancer Stocks to Buy to Boost Your Portfolio's Health

Zacks

7 months ago

Top Cancer Stocks to Buy to Boost Your Portfolio's Health

MT Newswires

7 months ago

Jefferies Initiates Verastem at Buy With $15 Price Target

MT Newswires

7 months ago

Mizuho Securities Adjusts Verastem Price Target to $8 From $9, Maintains Outperform Rating

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

7 months ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade

Zacks

7 months ago

Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

Business Wire

8 months ago

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

MT Newswires

8 months ago

RBC Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating

Associated Press Finance

8 months ago

Verastem: Q4 Earnings Snapshot

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Business Wire

8 months ago

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

Business Wire

9 months ago

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

MT Newswires

9 months ago

B. Riley Adjusts Verastem's Price Target to $9 From $7, Maintains Buy Rating

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Business Wire

9 months ago

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Business Wire

10 months ago

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

MT Newswires

10 months ago

Verastem Names Matthew E. Ros as COO

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

Business Wire

10 months ago

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

MT Newswires

10 months ago

Verastem Exercises Option Early to License Cancer Drug VS-7375 From GenFleet

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Business Wire

10 months ago

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

Business Wire

10 months ago

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

10 months ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

10 months ago

RBC Raises Price Target on Verastem to $16 From $13, Keeps Outperform, Speculative Risk

VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag

Zacks

10 months ago

VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag

Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy Application

GuruFocus.com

10 months ago

Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy Application

MT Newswires

10 months ago

Traders Cautious as 2024 Draws to Close, Stifling US Equity Futures Pre-Bell

MT Newswires

10 months ago

Top Premarket Gainers

MT Newswires

10 months ago

BTIG Raises Price Target on Verastem to $20 From $13, Keeps Buy Rating

MT Newswires

10 months ago

Verastem's Ovarian Cancer Drug Application Accepted by FDA, Gets Priority Review

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Business Wire

10 months ago

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Applied Therapeutics Appoints John H. Johnson as Executive Chairman

GlobeNewswire

a year ago

Applied Therapeutics Appoints John H. Johnson as Executive Chairman

MT Newswires

a year ago

Mizuho Raises Price Target on Verastem to $9 From $7, Keeps Outperform Rating

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Business Wire

a year ago

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

Business Wire

a year ago

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

Associated Press Finance

a year ago

Verastem: Q3 Earnings Snapshot

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Business Wire

a year ago

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology submits NDA for ovarian cancer treatment

Pharmaceutical Technology

a year ago

Verastem Oncology submits NDA for ovarian cancer treatment

MT Newswires

a year ago

Verastem Completes Rolling NDA Submission to US FDA for Drug Combination to Treat Rare Ovarian Cancer

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Business Wire

a year ago

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology to Participate in Upcoming Investor Conferences

Business Wire

a year ago

Verastem Oncology to Participate in Upcoming Investor Conferences

MT Newswires

a year ago

Verastem Reports Updated Data on Phase 2 Study of Ovarian Cancer Combination Therapy

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting

Business Wire

a year ago

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

Business Wire

a year ago

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

a year ago

Guggenheim Initiates Coverage on Verastem With Buy Rating, $13 Price Target

Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference

Business Wire

a year ago

Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference

Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting

Business Wire

a year ago

Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting

Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024

Business Wire

a year ago

Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024

MT Newswires

a year ago

RBC Adjusts Price Target on Verastem to $13 From $16, Maintains Outperform Rating

Associated Press Finance

a year ago

Verastem: Q2 Earnings Snapshot

Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates

Business Wire

a year ago

Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates

MT Newswires

a year ago

Verastem Gets FDA Orphan Drug Designation for Avutometinib With Defactinib to Treat Pancreatic Cancer

Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer

Business Wire

a year ago

Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer

MT Newswires

a year ago

B. Riley Adjusts Verastem's PT to $7 From $21, Maintains Buy Rating

MT Newswires

a year ago

Top Premarket Decliners

Share on Social Networks: